After the operation, each person receives one of the two medicines through a vein. The treatment is given in the recovery period after surgery, and the medical team follows the person during the hospital stay to watch how the heart, lungs, kidneys, and other organs recover. The study is open label, which means the treatment is known to the medical team and the person receiving it.

The main outcome is the change in mean pulmonary arterial pressure, which is the pressure in the main blood vessel carrying blood from the heart to the lungs. Other hospital problems may also be watched, such as kidney failure, atrial fibrillation or atrial flutter (irregular heart rhythms), stroke, pneumonia, bleeding from the airways, and death. The study is planned to run over several years while enough people are enrolled and followed after surgery.

The purpose of this research is to determine if it is safe to stop taking riociguat in patients whose blood pressure in the lungs has improved after the balloon procedure. The medication is given as film-coated tablets, with patients taking up to 7.5 milligrams per day. Some patients will continue taking riociguat, while others will stop the medication.

The study will last 16 weeks, during which doctors will monitor the blood pressure in patients’ lungs and other health measures. Throughout the study, various tests will be performed to check how well the heart and lungs are working, including measurements of exercise capacity and quality of life. This will help determine if stopping the medication is a safe option for patients who have shown improvement after their procedure.

Participants in the study will be assigned to receive either the active medication, levosimendan, or a placebo, which is an inactive substance, through an oral hard gelatin capsule. This assignment is done through a randomized process, meaning it is determined by chance, and a double-blind method, where neither the participants nor the researchers know which substance is being administered. The treatment period lasts for 26 weeks, during which the effects on physical activity and general health are monitored.

Participants in the study will be assigned to receive either L606 or a placebo. This research involves a randomized and double-blind process, meaning that neither the participants nor the researchers know which specific treatment is being administered until the study is finished. The study will monitor how the medication affects the ability to walk and other health factors over a period of time.

The purpose of this study is to find out if treating patients who have pulmonary hypertension and iron deficiency with ferric carboxymaltose improves their ability to exercise compared to those who receive placebo. The study will measure this by looking at changes in how far patients can walk in six minutes, which is a common way to check exercise ability in people with heart and lung conditions. The study will also look at other aspects such as quality of life, heart failure symptoms, and fatigue levels to see if the treatment helps patients feel better overall.

During the study, patients will be randomly assigned to receive either ferric carboxymaltose or placebo over a treatment period of up to four weeks. The study is double-blind, which means neither the patients nor the doctors will know who is receiving the actual medicine or placebo during the treatment. Patients will be followed for 24 weeks to see how well the treatment works. The study includes patients with different types of pulmonary hypertension, and all participants must have iron deficiency confirmed by blood tests before joining the study.

During the study, people will be randomly assigned to receive either treprostinil palmitil inhalation powder or placebo. The medicine is taken by breathing it in through the mouth using an inhaler device. The study will measure how far people can walk in six minutes, which is called a six-minute walk test. This test helps doctors understand how well the lungs and heart are working together. The study will also look at other things like blood test results that show how the heart is functioning, how long it takes before symptoms get worse, and how the disease affects daily life and symptoms.

The main part of the study lasts for 24 weeks, which is about six months. During this time, people will visit the study site for regular check-ups and tests. The study will measure changes in walking distance at different times during treatment. Blood samples will be taken to measure levels of certain substances in the blood and to check how the medicine is working in the body. The study will also track any major health problems that might happen and will ask people questions about their symptoms and how they feel in their daily activities.

The purpose of this study is to evaluate the long-term safety and tolerability of sotatercept over a period of up to 42 months. Participants in the study will receive sotatercept through subcutaneous injections, which means the medication is injected under the skin. The study will monitor participants for any adverse events, which are unwanted effects that may occur during the treatment. Additionally, the study will assess changes in participants’ ability to walk a certain distance in six minutes, as well as changes in their heart function and blood pressure in the lungs over time.

This study is an extension of previous research and aims to provide more information on how well sotatercept works and how safe it is for people with pulmonary hypertension. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the effectiveness of the treatment. The study is expected to continue until 2029, allowing researchers to collect comprehensive data on the long-term effects of sotatercept.

The purpose of the study is to evaluate the effect of TX000045 on the blood flow resistance in the lungs, known as Pulmonary Vascular Resistance (PVR), and to assess the safety of the medication. Participants in the study will receive either TX000045 or a placebo for a period of 24 weeks. During this time, they will have regular check-ups and tests to monitor their health and the effects of the treatment. These tests will include measuring PVR using a procedure called right heart catheterization (RHC), which involves inserting a thin tube into the heart to measure pressure and blood flow.

Throughout the study, participants will also undergo a 6-minute walk test (6MWT), which measures how far they can walk in six minutes, to assess their physical capacity. The study aims to see if there are any changes in the participants’ ability to walk and in their heart and lung function after receiving the treatment. The safety of TX000045 will be closely monitored by checking for any side effects or changes in health through regular laboratory tests, heart monitoring with an electrocardiogram (ECG), and physical examinations. The study is designed to provide valuable information about the potential benefits and risks of TX000045 for patients with pulmonary hypertension related to heart failure with preserved ejection fraction.

Participants in the study will be randomly assigned to receive either Mosliciguat or a placebo. The study will last for about a year, during which participants will use the inhaler daily. The main focus will be on measuring changes in the blood flow resistance in the lungs at the end of 16 weeks. Additionally, the study will look at changes in the distance participants can walk in six minutes and levels of a specific protein in the blood that can indicate heart stress.

This trial aims to provide valuable information on whether Mosliciguat can help improve the condition of patients with pulmonary hypertension associated with interstitial lung disease. The results could potentially lead to new treatment options for managing this challenging condition.

The purpose of the study is to assess how effective and safe sotatercept is for people with Cpc-PH due to HFpEF. Participants in the study will receive either sotatercept or a placebo. The study will monitor changes in the participants’ health over time, focusing on how well their blood vessels function and their ability to walk a certain distance. The study will also keep track of any side effects or health changes that occur during the treatment period.

Participants will be involved in the study for a period of time, during which they will receive regular check-ups and assessments to monitor their condition and response to the treatment. The study aims to provide valuable information on whether sotatercept can be a beneficial treatment option for individuals with this specific type of pulmonary hypertension.

The treatment being studied is Conoxia, which is a medical-grade oxygen given in its liquid, extremely cold form (cryogenic). This pure oxygen will be administered to participants to examine its effects on blood circulation. The study will measure how the heart pumps blood and how blood vessels respond to this oxygen treatment.

During the study, measurements will be taken at different time points to see how quickly the body responds to the oxygen treatment. The study will look at blood flow changes in various parts of the body, including the heart’s small blood vessels and the blood vessels in the lungs. These measurements will help understand how oxygen treatment affects blood circulation throughout the body.

The purpose of the study is to compare the effectiveness of the dual medication treatment against the standard single medication treatment in reducing the resistance in the blood vessels of the lungs. Participants in the study will be newly diagnosed and have not received previous treatment for CTEPH. The study will involve taking the medications and undergoing various assessments over a period of time to monitor changes in the condition.

Throughout the study, participants will have their lung function and overall health monitored, including their ability to walk a certain distance in six minutes, their quality of life, and other health indicators. The study aims to provide insights into whether the dual medication approach offers better outcomes for patients with inoperable CTEPH compared to the standard treatment.

The purpose of the study is to evaluate how these medications perform in patients undergoing a procedure called Balloon Pulmonary Angioplasty (BPA). This procedure is used to open up blocked blood vessels in the lungs. The study will look at the occurrence of bleeding and lung injury within 24 hours after the procedure. Participants will receive one of the medications or a placebo, and their health will be monitored to see how well the medications work and how safe they are.

The study will take place over a period of time, with participants receiving treatment for up to 30 days. During this time, researchers will collect data on any complications, such as bleeding or lung issues, as well as other health outcomes like allergic reactions, kidney problems, and hospitalizations. The goal is to better understand which medication is most effective and safe for patients with CTEPH or CTED undergoing BPA.

The purpose of this study is to evaluate the long-term safety of these treatments in participants who have been using them in previous studies. Participants will take the medications in the form of film-coated tablets, which are taken orally. The study will follow participants over a period of time to monitor their health and any potential side effects that may occur while using these treatments.

Throughout the study, participants will be regularly monitored to ensure their safety and to gather information on how the treatments affect their condition. This will help researchers understand the long-term effects of these medications and provide valuable information for future treatment options for people with these lung conditions.

The purpose of the study is to assess how Riociguat affects the heart and blood flow in patients with pulmonary hypertension linked to left heart failure. Participants in the study will be randomly assigned to receive either Riociguat or a placebo. The study will be conducted over a period of time, during which participants will take the medication and undergo various tests to monitor their heart function and overall health. These tests will include measurements of blood pressure in the lungs and assessments of heart performance.

Throughout the study, the safety of Riociguat will be closely monitored, and blood samples will be collected to understand how the drug is processed in the body. The study aims to provide valuable information on the potential benefits and safety of Riociguat for patients with pulmonary hypertension associated with left ventricular systolic dysfunction. Participants will be followed up regularly to track any changes in their condition and to ensure their well-being during the trial.

The purpose of the study is to evaluate the safety and tolerability of long-term use of Treprostinil Palmitil Inhalation Powder in participants with Pulmonary Hypertension associated with Interstitial Lung Disease. Participants who have completed previous related studies are eligible to join this extension study. The study will monitor participants over a period of time to observe any side effects and to assess how well the treatment is tolerated. Participants will be asked to use the inhalation powder regularly and attend follow-up visits to track their progress.

Throughout the study, various health measurements will be taken to assess the effectiveness of the treatment. These include tests to measure lung function and exercise capacity, as well as blood tests to check for specific markers related to the disease. The study aims to provide valuable information on the long-term use of Treprostinil Palmitil Inhalation Powder, which could help improve treatment options for people with Pulmonary Hypertension associated with Interstitial Lung Disease.

Participants in the study will be randomly assigned to receive either Ralinepag or a placebo, which looks like the medication but does not contain the active substance. The study will monitor the time it takes for participants to experience a worsening of their condition, as defined by the study’s guidelines. This will help researchers determine the effectiveness of Ralinepag in delaying the progression of PAH. The study will also look at other factors, such as changes in exercise capacity and overall health status, to gather comprehensive data on the treatment’s impact.

The study will last for a period of up to 48 weeks, during which participants will have regular check-ups and assessments to track their health and any changes in their condition. This will include various tests and evaluations to ensure the safety and effectiveness of the treatment. The information gathered from this study will contribute to a better understanding of how Ralinepag can be used to manage PAH and improve the quality of life for those affected by this condition.

The purpose of this study is to evaluate the long-term safety and how well patients tolerate Ralinepag. Participants in this study have previously taken part in earlier phases of research involving Ralinepag. During the study, participants will continue to take the medication and attend regular visits to monitor their health and the effects of the treatment. The study will assess various health indicators, such as levels of a specific protein in the blood, the distance a patient can walk in six minutes, and overall quality of life. These assessments help researchers understand how the medication impacts the condition over an extended period.

This study is an open-label extension, meaning that all participants will receive Ralinepag, and there is no placebo group. The study aims to provide valuable information on the long-term use of Ralinepag for managing pulmonary arterial hypertension, contributing to a better understanding of its safety and effectiveness for patients with this condition.

The purpose of the study is to evaluate the effect of MK-5475 on the distance participants can walk in six minutes, known as the 6-minute walk distance, after 24 weeks. Participants will be randomly assigned to receive either MK-5475 or a placebo. The study will last for several months, during which participants will have regular check-ups to monitor their health and the effects of the treatment. The study aims to see if MK-5475 can help improve the ability to walk longer distances and assess its safety for people with PH-COPD.

Throughout the study, participants will be closely monitored for any changes in their condition and any side effects they might experience. The study will also look at other health indicators, such as levels of a substance called N-terminal pro B-type natriuretic peptide (NT-proBNP), which can be a marker of heart stress, and the overall health status of participants as classified by the World Health Organization (WHO). The goal is to gather information that could lead to better treatment options for people living with PH-COPD.

Participants in the study will be randomly assigned to receive either dapagliflozin or a placebo, which is a tablet that looks like the medication but does not contain the active ingredient. The study will last for about three months, during which participants will take the tablets by mouth. Throughout the study, various tests will be conducted to assess changes in exercise ability, heart and lung function, and other health indicators. These tests will help researchers understand the impact of dapagliflozin on the body.

The study aims to provide valuable information on whether dapagliflozin can improve the health and quality of life for people with PAH. By comparing the effects of the medication with the placebo, researchers hope to determine its effectiveness and safety in managing this challenging condition. Participants will be closely monitored by healthcare professionals throughout the study to ensure their well-being and to gather accurate data on the medication’s effects.